SCHEMBL862175

SCHEMBL862175

CCOC(=O)Nc1cccc(S(=O)(=O)NC(=O)c2c(-c3ccc[nH]c3=O)c3cc(Cl)ccc3n2Cc2ccccc2F)c1

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.41
CYP2C8 P10632 1/20 0.40
KMT2A Q03164 5/20 0.37
MEN1 O00255 3/20 0.37
PTGDR2 Q9Y5Y4 1/20 0.36
LMNA P02545 4/20 0.35
ALDH1A1 P00352 1/20 0.35
HPGD P15428 1/20 0.35
APOBEC3G Q9HC16 1/20 0.35
PPARG P37231 3/20 0.35
THRB P10828 2/20 0.34
IDH1 O75874 1/20 0.34
RIPK3 Q9Y572 1/20 0.34
POLB P06746 1/20 0.33
NPY1R P25929 1/20 0.33
NPY2R P49146 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL862042 0.94 CYP2C8 (0.38) MAPTCYP2C8KMT2AMEN1PTGDR2
SCHEMBL862574 0.89 CYP2C8 (0.41) MAPTCYP2C8KMT2AMEN1PTGDR2
SCHEMBL10255303 0.85 CYP2C8 (0.39) MAPTCYP2C8KMT2AMEN1PTGDR2
SCHEMBL831382 0.84 CYP2C8 (0.40) CYP2C8KMT2AMEN1PTGDR2PPARG
SCHEMBL862268 0.84 AGTR1 (0.40) MAPTCYP2C8KMT2AMEN1LMNA
SCHEMBL862460 0.83 CYP2C8 (0.41) CYP2C8KMT2APTGDR2PPARG
SCHEMBL831655 0.83 CYP2C8 (0.46) MAPTCYP2C8KMT2AMEN1PTGDR2
SCHEMBL862454 0.83 CYP2C8 (0.39) MAPTCYP2C8KMT2APPARGTHRB
SCHEMBL10258012 0.83 CYP2C8 (0.38) MAPTCYP2C8KMT2AMEN1PTGDR2
SCHEMBL862590 0.83 CYP2C8 (0.39) MAPTCYP2C8KMT2AMEN1PTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143305-B2 2,3-substituted indole derivatives for treating viral infections SCHERING CORPORATION (US) 2012-03-27 US disclosed
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS MERCK SHARP & DOHME CORP. 2011-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS IDO2, IDO1, IRF3 MAPT 1047/4885CYP2C8 847/4885KMT2A 321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.